Background:

Immunotherapy consists of the administration of the allergen increasing doses to control sensitivity towards it.

Objective:

To describe the behavior of subcutaneous or sublingual immunotherapy to mites.

Methodology:

Retrospective study carried out in Cabaiguán, from 2010 to 2019, the universe of 267 patients with positive tests to mites and the sample 53 patients. Data were obtained from the data record.

Results:

60.4 % used sublingual, the age group between 5-18 years prevailed (41.5 %), the subcutaneous was used in 39.6 %, and it was more frequent in males (58.5 %). The subcutaneous was indicated mainly in allergic rhinitis (20.7 %) and sublingual in asthma (32.1 %); for both, Dermatofagoide pteronyssinus was the highest sensitivity and use mite (43.4 %) the dominant administration time was 3 years (67.9 %). Symptom control was achieved by sublingual (37.7 %). In sublingual, there were no adverse events in 43.3 %, with the subcutaneous, 11.3 % of the adverse events were local and 7.6 % were mild systemic.

Conclusions:

Sublingual was the most used, the one with the highest control of symptoms and the fewest adverse events in the study.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )